[go: up one dir, main page]

UA101167C2 - Фармацевтическая композиция, предназначенная для лечения глазной болезни - Google Patents

Фармацевтическая композиция, предназначенная для лечения глазной болезни

Info

Publication number
UA101167C2
UA101167C2 UAA201005123A UAA201005123A UA101167C2 UA 101167 C2 UA101167 C2 UA 101167C2 UA A201005123 A UAA201005123 A UA A201005123A UA A201005123 A UAA201005123 A UA A201005123A UA 101167 C2 UA101167 C2 UA 101167C2
Authority
UA
Ukraine
Prior art keywords
ocular disease
treatment
pharmaceutical composition
composition useful
ocular
Prior art date
Application number
UAA201005123A
Other languages
English (en)
Ukrainian (uk)
Inventor
Андреа ПФАЙФЕР
Мария ПИЛГРЕН
Андреас МУС
Райан Воттс
Original Assignee
Дженентек, Инк.
Ас Иммуне С.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Дженентек, Инк., Ас Иммуне С.А. filed Critical Дженентек, Инк.
Publication of UA101167C2 publication Critical patent/UA101167C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Изобретение относится к фармацевтической композиции, предназначенной для лечения глазной болезни, ассоциированной с патологическими аномалиями в тканях зрительной системы, которая содержит антитело, которое специфично связывается с β-амилоидным белком, способу диагностики глазной болезни и способу мониторинга минимальных остаточных признаков глазной болезни.
UAA201005123A 2007-10-05 2008-10-03 Фармацевтическая композиция, предназначенная для лечения глазной болезни UA101167C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US96061607P 2007-10-05 2007-10-05
PCT/US2008/011491 WO2009048537A2 (en) 2007-10-05 2008-10-03 Humanized antibody

Publications (1)

Publication Number Publication Date
UA101167C2 true UA101167C2 (ru) 2013-03-11

Family

ID=40549776

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201005123A UA101167C2 (ru) 2007-10-05 2008-10-03 Фармацевтическая композиция, предназначенная для лечения глазной болезни

Country Status (14)

Country Link
US (2) US20100297013A1 (ru)
EP (1) EP2205631B1 (ru)
CN (2) CN101883791B (ru)
AU (2) AU2008311365B2 (ru)
BR (1) BRPI0818621A8 (ru)
CA (1) CA2701788C (ru)
ES (1) ES2612788T3 (ru)
IL (1) IL204835A0 (ru)
NZ (2) NZ585110A (ru)
RU (1) RU2538709C2 (ru)
SG (1) SG185277A1 (ru)
UA (1) UA101167C2 (ru)
WO (1) WO2009048537A2 (ru)
ZA (1) ZA201003028B (ru)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
CA2628703C (en) 2005-11-30 2019-10-29 Abbott Laboratories Anti-a.beta. globulomer antibodies, antigen-binding moieties thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods of producing said antibodies, compositions comprising said antibodies, uses of said antibodies and methods of using said antibodies
DK1976877T4 (en) 2005-11-30 2017-01-16 Abbvie Inc Monoclonal antibodies to amyloid beta protein and uses thereof
PL2468770T3 (pl) 2006-07-14 2018-07-31 Ac Immune S.A. Humanizowane przeciwciało przeciw amyloidowi beta
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
WO2008104386A2 (en) 2007-02-27 2008-09-04 Abbott Gmbh & Co. Kg Method for the treatment of amyloidoses
US8048420B2 (en) 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
US8613923B2 (en) * 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
DK2238166T3 (da) 2007-10-05 2014-01-27 Ac Immune Sa Anvendelse af et anti-amyloid-beta-antistof ved øjensygdomme
CN104744591B (zh) 2010-04-15 2022-09-27 Abbvie德国有限责任两合公司 β淀粉样蛋白结合蛋白
AU2011282536B2 (en) 2010-07-30 2015-12-24 Ac Immune S.A. Safe and functional humanized anti beta-amyloid antibody
WO2012024187A1 (en) 2010-08-14 2012-02-23 Abbott Laboratories Amyloid-beta binding proteins
ES2915378T3 (es) 2013-09-13 2022-06-22 Hoffmann La Roche Procedimientos para detectar y cuantificar una proteína de célula huésped en líneas celulares
KR102571391B1 (ko) 2013-09-13 2023-08-29 제넨테크, 인크. 정제된 재조합 폴리펩티드를 포함하는 방법 및 조성물
CN107074938A (zh) * 2014-10-16 2017-08-18 豪夫迈·罗氏有限公司 抗‑α‑突触核蛋白抗体和使用方法
EP3374379A4 (en) 2015-11-09 2019-05-15 The University Of British Columbia N-TERMINAL EPITOPES IN AMYLOID BETA AND CONFORMATION-SELECTIVE ANTIBODIES
WO2017079835A1 (en) 2015-11-09 2017-05-18 The University Of British Columbia Amyloid beta epitopes and antibodies thereto
EP3374381A4 (en) 2015-11-09 2019-05-15 The University Of British Columbia EPITOPES IN THE AMYLOID-BETA MEDIUM REGION AND CONFORMITY-SELECTIVE ANTIBODIES THEREOF
IL263223B2 (en) * 2016-05-27 2023-03-01 Abbvie Biotherapeutics Inc Antibodies against cd40 and their uses
CN109476729A (zh) 2016-07-18 2019-03-15 英属哥伦比亚大学 淀粉样蛋白β的抗体
US20180125920A1 (en) 2016-11-09 2018-05-10 The University Of British Columbia Methods for preventing and treating A-beta oligomer-associated and/or -induced diseases and conditions
US12286469B2 (en) 2017-07-18 2025-04-29 The University Of British Columbia Humanized antibodies binding to amyloid-beta (A-beta)
CN111094340B (zh) * 2018-07-17 2022-11-22 江苏恒瑞医药股份有限公司 抗Abeta抗体、其抗原结合片段及应用
CN113508127A (zh) 2018-11-06 2021-10-15 阿尔萨泰克公司 神经变性疾病的基于细胞的基因疗法

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0307434B2 (en) * 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
US5837822A (en) * 1992-01-27 1998-11-17 Icos Corporation Humanized antibodies specific for ICAM related protein
US5811517A (en) * 1992-01-27 1998-09-22 Icos Corporation ICAM-related protein variants
EP0729976A1 (en) * 1993-11-19 1996-09-04 Chugai Seiyaku Kabushiki Kaisha Reconstituted human antibody against human medulloblastomatous cell
EP1017375A2 (en) * 1997-09-24 2000-07-12 Nova Molecular, Inc. Methods for increasing apoe levels for the treatment of neurodegenerative disease
TWI239847B (en) * 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US7179892B2 (en) * 2000-12-06 2007-02-20 Neuralab Limited Humanized antibodies that recognize beta amyloid peptide
DE69920897T2 (de) * 1998-04-28 2005-10-13 Smithkline Beecham Corp. Monoklonale antikörper mit verringerter immunisierungsfähigkeit
US6737056B1 (en) * 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US6998124B1 (en) * 1999-04-14 2006-02-14 Smithkline Beecham Corporation Erythropoietin receptor antibodies
ATE405636T1 (de) * 1999-06-16 2008-09-15 Boston Biomedical Res Inst Immunologische kontrolle des beta-amyloid gehaltes in vivo
ATE283487T1 (de) * 1999-09-01 2004-12-15 Evotec Neurosciences Gmbh Verfahren zur diagnose oder prognose von altersbedingter maculadegeneration
US20040013647A1 (en) * 1999-09-03 2004-01-22 Ramot At Tel-Aviv University Ltd. Methods and compositions for treating a plaque-forming disease
WO2001062801A2 (en) * 2000-02-24 2001-08-30 Washington University Humanized antibodies that sequester amyloid beta peptide
US6750210B2 (en) * 2000-08-05 2004-06-15 Smithkline Beecham Corporation Formulation containing novel anti-inflammatory androstane derivative
US6638722B2 (en) * 2001-06-13 2003-10-28 Invitrogen Corporation Method for rapid amplification of DNA
EP1420032B2 (en) * 2001-08-03 2015-12-16 Medical & Biological Laboratories Co., Ltd. Antibody recognizing gm1 ganglioside-bound amyloid beta-protein and dna encoding the antibody
EP1944040B1 (en) * 2001-08-17 2012-08-01 Washington University Assay method for Alzheimer's disease
AR038568A1 (es) * 2002-02-20 2005-01-19 Hoffmann La Roche Anticuerpos anti-a beta y su uso
EP1439192A1 (en) * 2003-01-15 2004-07-21 Xerion Pharmaceuticals AG Neuropilin-1 inhibitors
JP2006524039A (ja) * 2003-01-09 2006-10-26 マクロジェニクス，インコーポレーテッド 変異型Ｆｃ領域を含む抗体の同定および作製ならびにその利用法
AT413945B (de) * 2003-01-14 2006-07-15 Mattner Frank Dr Impfstoff für die alzheimer-krankheit
DE10303974A1 (de) * 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
WO2004071408A2 (en) * 2003-02-10 2004-08-26 Applied Molecular Evolution, Inc. Aβ BINDING MOLECULES
RU2271208C2 (ru) * 2003-03-31 2006-03-10 Кировская клиническая офтальмологическая больница Способ лечения сенильной макулярной дегенерации с неоваскулярным синдромом
TWI306458B (en) * 2003-05-30 2009-02-21 Elan Pharma Int Ltd Humanized antibodies that recognize beta amyloid peptide
CN100426423C (zh) * 2004-01-06 2008-10-15 上海长园维安电子线路保护股份有限公司 一种陶瓷正温度系数热敏电阻阻值调整的方法
JP4824547B2 (ja) * 2004-02-20 2011-11-30 インテレクト ニュウロサイエンシス，インク． モノクローナル抗体およびその利用
CA2564432A1 (en) * 2004-04-27 2005-11-10 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Human anti-amyloid .beta. peptide antibody and fragment of said antibody
SE0401601D0 (sv) * 2004-06-21 2004-06-21 Bioarctic Neuroscience Ab Protofibril specific antibodies and uses thereof
CA2575663C (en) * 2004-07-30 2013-04-23 Rinat Neuroscience Corp. Antibodies directed against amyloid-beta peptide and methods using same
WO2006039327A2 (en) * 2004-10-01 2006-04-13 Merck & Co., Inc. Methods of treatment or prophylaxis of amyloidogenic diseases of the eye or optic nerve
US7780963B2 (en) * 2004-10-25 2010-08-24 Merck & Co., Inc. Anti-ADDL antibodies and uses thereof
ES2396555T3 (es) * 2004-12-15 2013-02-22 Janssen Alzheimer Immunotherapy Anticuerpos que reconocen péptido beta amiloide
GT200600031A (es) * 2005-01-28 2006-08-29 Formulacion anticuerpo anti a beta
ES2259270B1 (es) * 2005-03-09 2007-11-01 Consejo Superior De Investigaciones Cientificas Metodo de diagnostico in vitro de la enfermedad de alzheimer mediante un anticuerpo monoclonal.
UY29504A1 (es) * 2005-04-29 2006-10-31 Rinat Neuroscience Corp Anticuerpos dirigidos contra el péptido amiloide beta y métodos que utilizan los mismos.
CA2611815A1 (en) * 2005-06-17 2006-12-28 Elan Pharma International Limited Methods of purifying anti a beta antibodies
MX358175B (es) * 2005-12-12 2018-08-08 Ac Immune Sa Anticuerpos monoclonales especificos 1-42 beta con propiedades terapeuticas.
EP1996621B1 (en) * 2006-03-30 2009-12-09 Glaxo Group Limited Antibodies against amyloid-beta peptide
PL2468770T3 (pl) * 2006-07-14 2018-07-31 Ac Immune S.A. Humanizowane przeciwciało przeciw amyloidowi beta
BRPI0719763A2 (pt) * 2006-10-02 2014-01-28 Ac Immune Sa Anticorpo, molécula de ácido nucleico, vetor de expressão, célula, composição, mistura, uso de um anticorpo quimérico ou um fragmento do mesmo ou um anticorpo humanizado ou um fragmento do mesmo e/ou uma parte funcional e/ou uma composição farmacêutica ou uma mistura, métodos para a preparação de uma composição farmacêutica ou de uma mistura, para prevenir, tratar ou aliviar os efeitos de uma doença, de diagnóstico de uma doença ou condição associada com amilóide em um paciente e de determinação do grau da carga de placa amiloidogênica em um tecido e/ou fluidos corporais, kits de teste para a detecção e diagnóstico de doenças e condições associadas com amilóide, região variável de cadeia leve, região variável de cadeia pesada, linhagem de célula, gene de anticorpo, e, métodos para desagregar fibras de beta-amilóide pré formadas, para prevenir a degradação de neurônio induzida por abeta, para diagnosticar uma predisposição a uma doença ou condição associada com amilóide em um paciente, para monitorar doença residual mínima em um paciente, para prognosticar a responsividade de um paciente que é tratado com um anticorpo ou uma composição de vacina, para reduzir a carga de placa no cérebro de um animal, para reduzir a quantidade de placas no cérebro de um animal, para diminuir a quantidade total de abeta solúvel no cérebro de um animal e para reter ou aumentar a capacidade de memória cognitiva em um mamífero.
MX2009005279A (es) * 2006-11-24 2009-05-28 Ac Immune Sa Derivados de n-(metil)-1h-pirazol-3-amina, n-(metil)-piridin-2-ami na y n-(metil)-tiazol-2-amina para el tratamiento de enfermedades asociadas con proteinas amiloides o tipo amiloide, tal como por ejemplo alzheimer.
US8455626B2 (en) * 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
US20090022728A1 (en) * 2007-03-09 2009-01-22 Rinat Neuroscience Corporation Methods of treating ophthalmic diseases
TWI557136B (zh) * 2007-06-12 2016-11-11 Ａｃ免疫公司 特異性結合β-類澱粉蛋白之抗體及相關核酸分子、表現載體、細胞、組合物、套組、方法及用途
US8048420B2 (en) * 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
US8613923B2 (en) * 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
AU2008311366B2 (en) * 2007-10-05 2015-03-12 Ac Immune S.A. Use of anti-amyloid beta antibody in ocular diseases
DK2238166T3 (da) * 2007-10-05 2014-01-27 Ac Immune Sa Anvendelse af et anti-amyloid-beta-antistof ved øjensygdomme
JO3076B1 (ar) * 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
US8621045B2 (en) * 2008-09-12 2013-12-31 At&T Intellectual Property I, L.P. Portable communication interface for accessing media content
AU2011282536B2 (en) * 2010-07-30 2015-12-24 Ac Immune S.A. Safe and functional humanized anti beta-amyloid antibody

Also Published As

Publication number Publication date
SG185277A1 (en) 2012-11-29
AU2008311365B2 (en) 2015-03-12
AU2015200844A1 (en) 2015-03-12
ZA201003028B (en) 2018-11-28
US20160244514A1 (en) 2016-08-25
NZ601858A (en) 2014-03-28
ES2612788T3 (es) 2017-05-18
CA2701788A1 (en) 2009-04-16
NZ585110A (en) 2012-09-28
IL204835A0 (en) 2010-11-30
AU2015200844B2 (en) 2016-12-15
CN101883791B (zh) 2015-11-25
RU2538709C2 (ru) 2015-01-10
BRPI0818621A2 (pt) 2017-05-23
AU2008311365A1 (en) 2009-04-16
EP2205631B1 (en) 2016-11-23
EP2205631A2 (en) 2010-07-14
CN101883791A (zh) 2010-11-10
RU2010116822A (ru) 2011-11-10
US20100297013A1 (en) 2010-11-25
WO2009048537A2 (en) 2009-04-16
BRPI0818621A8 (pt) 2018-01-30
CN105169388A (zh) 2015-12-23
WO2009048537A3 (en) 2009-09-03
CA2701788C (en) 2017-06-13

Similar Documents

Publication Publication Date Title
UA101167C2 (ru) Фармацевтическая композиция, предназначенная для лечения глазной болезни
EP2987807A3 (en) Antibodies recognising phospho-tau
WO2009048538A3 (en) Use of anti-amyloid beta antibody in ocular diseases
WO2010118035A3 (en) Biomarkers for monitoring treatment of neuropsychiatric diseases
EP2586795A3 (en) Use of anti-amyloid beta antibody in ocular diseases
WO2010059969A3 (en) Use of anti-vegf antibody in combination with chemtherapy for treating breast cancer
WO2008013859A3 (en) Peptide probes for diagnostics and therapeutics
WO2009085216A3 (en) Compositions and methods for detecting or elimninating senescent cells to diagnose or treat disease
MX354662B (es) Anticuerpos fosfoespecificos que reconocen la tau.
WO2006127861A3 (en) Diagnosis of diseases and conditions by analysis of histopathologically processed biological samples using liquid tissue preparations
WO2006020269A3 (en) Biomarkers of neurodegenerative disease
MX356800B (es) Anticuerpo tau humanizado.
MX2009012950A (es) ANTICUERPOS HUMANIZADOS CONTRA EL GLOBULOMERO Aß (20-42) Y SUS USOS.
ATE553778T1 (de) Für humanes hepcidin spezifische antikörper
WO2012040727A3 (en) Methods for diagnosis and treatment of neurodegenerative diseases or disorders
EP2175879A4 (en) TREATMENT OF DISEASES ASSOCIATED WITH PRION PROTEIN
IL190841A0 (en) Pharmaceutical compositions and diagnostic methods for inflammatory skin diseases, disorders or conditions
WO2010047938A3 (en) Mmp activation peptide detection in biological samples
WO2010054377A3 (en) Fully human antibodies against n-cadherin
WO2010115034A3 (en) Protein biomarkers for soft tissue disease diagnosis and as therapeutic targets for oral care intervention
WO2007094027A8 (en) Methods for the diagnosis of proliferative and/or conformational diseases
SG170804A1 (en) Pseudomonas aeruginosa outer membrane protein pa0427
WO2013063412A3 (en) Methods of diagnosis and treatment of endoplasmic reticulum (er) stress-related conditions
WO2011045383A3 (en) 2, 6 -diaminopyridine compounds for treating diseases associated with amyloid proteins or for treating ocular diseases
WO2008103202A3 (en) Hypoxia related genes and proteins for the treatment and diagnosis of pregnancy related complications